Seminars in Cancer Biology, Год журнала: 2023, Номер 92, С. 128 - 129
Опубликована: Апрель 5, 2023
Язык: Английский
Medicine, Год журнала: 2025, Номер 104(12), С. e41953 - e41953
Опубликована: Март 21, 2025
Clinically, approximately 10% to 20% of small cell lung cancer (SCLC) patients do not respond well initial platinum-based first-line chemotherapy. Knowledge about the clinicopathologic characteristics these primary drug-resistant populations is limited. This study aimed explore in SCLC insensitive enrolled with insensitivity chemotherapy and analyzed their clinicopathological characteristics. Binary logistic regression analysis was used determine independent factors that influence chemosensitivity. The evaluated 142 cases Between chemotherapy-insensitive group (n = 32) chemotherapy-sensitive 110), no significant differences were observed sex, age, smoking status, tumor size, lymph-node metastasis, vascular invasion, carcinomatous lymphangitis, mediastinal superior vena cava syndrome, stage, brain metastases, pleural adrenal or immunohistochemical markers cytokeratin, synaptophysin, chromogranin A, thyroid transcription factor-1, Ki-67 (all P > .05). However, liver metastasis (P .005), bone < .001), neural adhesion molecule expression .027) identified. revealed .008) an high-risk factor for Bone SCLC. Enhancing our understanding biology osteoimmuno-oncology could identify new vulnerabilities better define patient may benefit from tailored clinical treatments overcome drug resistance.
Язык: Английский
Процитировано
0
Korean Journal of Radiology, Год журнала: 2025, Номер 26(6), С. 593 - 593
Опубликована: Янв. 1, 2025
Molecular subtyping of small-cell lung cancer (SCLC) has major implications for prognostic relevance and treatment guidance. This study aimed to explore the feasibility a novel tracer targeting C-X-C-chemokine-receptor-type-4 (CXCR4) distinguishing different SCLC subtypes. Thirty-five patients with pathologically confirmed were enrolled in this prospective study. Immunohistochemical staining was performed classify molecular subtypes into SCLC-A, SCLC-N, SCLC-P, SCLC-I. [¹⁸F]AlF-NOTA-QHY-04 PET/CT parameters obtained, including maximum, mean, peak standard uptake values (SUVmax, SUVmean, SUVpeak, respectively) ratios tumors (T) normal tissues (NT) based on SUVmax (T/NT). These compared among A receiver operating characteristic (ROC) curve used analyze performance SCLC-N from other neuroendocrine (NE) (SCLC-A SCLC-N) non-NE (SCLC-P SCLC-I). The SCLC-A (n = 17), 6), SCLC-P 7), SCLC-I 5). subtype exhibited significantly higher both primary lymph node metastases than three (P < 0.05). When combined (referred as "other SCLCs"), all group ROC analysis showed that these had high accuracy SCLCs (area under curve: 0.868-0.948 0.783-0.888 metastases). Compared group, SUVmax, T/NTlung NE tumors. moderate between groups (ROC area: 0.692-0.786 0.692-0.815 Our preliminary findings indicate CXCR4-directed imaging using may differentiate SCLC.
Язык: Английский
Процитировано
0
Molecular Biology Reports, Год журнала: 2023, Номер 50(10), С. 8015 - 8023
Опубликована: Авг. 4, 2023
Язык: Английский
Процитировано
7
Digestive Diseases and Sciences, Год журнала: 2024, Номер 69(5), С. 1562 - 1570
Опубликована: Апрель 5, 2024
Esophageal carcinoma (ESCA) is an aggressive solid tumor. The 5-year survival rate for patients with ESCA estimated to be less than 20%, mainly due tumor invasion and metastasis. Therefore, it urgent improve early diagnostic tools effective treatments patients. Tumor microenvironment (TME) enhances the ability of cells proliferate, migrate, escape from immune system, thus promoting occurrence development TME contains chemokines. Chemokines consist four major families, which are composed CC CXC families. main purpose this review understand chemokines their receptors in ESCA, understanding tumorigenesis determine new biomarkers diagnosis prognosis ESCA. We reviewed literature on identified by PubMed database. This article introduces general structures functions CC, TME, as well roles progress involved such cancer cell invasion, metastasis, angiogenesis, radioresistance, key determinants disease progression, have a great impact patient treatment response. In addition, full mechanism action essential further verify that these may serve or therapeutic targets poor esophageal related metastasis Tumor-associated macrophages highly correlated occurrence, development, severity, microenvironment. Studies shown tumor-associated can secrete variety A comprehensive analysis relationship between found binding corresponding regulate growth, migration radiotherapy resistance leukocyte
Язык: Английский
Процитировано
2
The FASEB Journal, Год журнала: 2024, Номер 38(14)
Опубликована: Июль 22, 2024
Abstract Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis reduced survival rates. However, only few pan‐cancer analyses targeted SPP1. We conducted comprehensive analysis using public databases, including TIMER TCGA, to investigate the of 33 different tumor types. In addition, we verified effect on osteosarcoma. To assess impact patient outcomes, employed univariate Cox regression Kaplan–Meier analyze overall (OS), disease‐specific (DSS), progression‐free interval (PFI) these patients. explored gene alterations various tissues cBioPortal. then examined relationship between clinical characteristics, TME, immune regulatory genes, checkpoints, TMB, MSI R language. used GSEA molecular mechanisms underlying role Bioinformatics indicated that was upregulated 17 tumors. Overexpression results OS, DSS, PFI CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, skin cutaneous melanoma. positively immunocyte infiltration, MSI, drug sensitivity certain cancers. found high osteosarcoma related resistance metastasis further demonstrated can stimulate cell proliferation via CCND1 by activating PI3K/Akt pathway. These findings strongly suggest potential prognostic marker novel target for cancer immunotherapy.
Язык: Английский
Процитировано
2
Cancer and Metastasis Reviews, Год журнала: 2024, Номер 44(1)
Опубликована: Ноя. 25, 2024
Язык: Английский
Процитировано
2
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown
Опубликована: Янв. 4, 2023
Abstract Small-cell-lung-cancer (SCLC) has the worst prognosis of all lung cancers because a high incidence relapse after therapy. We developed bioengineered 3-dimensional (3D) SCLC co-culture organoid as phenotypic tool to study tumor kinetics and SCLC-fibroblast interactions during relapse. used functionalized alginate microbeads scaffold mimic alveolar architecture co-cultured cell lines with primary adult fibroblasts (ALF). found that SCLCs in model proliferated extensively, invaded microbead formed tumors within just 7 days. compared patient them recapitulate pathology immunophenotyping better than PDX from same line. When treated standard chemotherapy drugs, etoposide cisplatin, recapitulated chemotherapy. Co-culture cells ALFs revealed play key role inducing faster more robust regrowth model. This was paracrine effect conditioned medium responsible for this accelerated regrowth. is also amenable throughput or targeted drug screening find new therapeutics SCLC.
Язык: Английский
Процитировано
4
Journal of Zhejiang University SCIENCE B, Год журнала: 2024, Номер unknown
Опубликована: Сен. 30, 2024
Язык: Английский
Процитировано
1
ImmunoTargets and Therapy, Год журнала: 2024, Номер Volume 13, С. 571 - 583
Опубликована: Окт. 1, 2024
Immune checkpoint inhibitors (ICIs) has prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC) as first-line treatment. However, whether ICI rechallenge could bring benefit to ES-SCLC following its failure treatment remains unknown. Therefore, we aim address the issue and identify cohort of that may derive such benefit.
Язык: Английский
Процитировано
1
Seminars in Cancer Biology, Год журнала: 2023, Номер 92, С. 128 - 129
Опубликована: Апрель 5, 2023
Язык: Английский
Процитировано
0